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Abstract
Background: Bone resorption displays marked diurnal variation. Reversible inhibition of bone
resorption may result in best possible efficacy when bone resorption peaks. The aim of the study
was to assess the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of 0.8 mg of oral
salmon calcitonin (sCT) and the effect of timing of drug intake.
Methods: The study was a randomized, double-blind, double-dummy, placebo-controlled, phase I
study to assess the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of 0.8 mg of oral sCT
in healthy postmenopausal women. Totally 81 subjects were included, aimed at investigation of a
morning dose given at 8:00 (n = 42), a pre-dinner dose given at 17:00 (n = 20), and an evening dose
given at 22:00 (n = 19). Plasma sCT concentrations and bone resorption (C-terminal-telopeptide
of collagen type I (CTX-I)) was assessed.
Results: Morning and pre-dinner dosing led to comparable concentration of sCT of 45 pg/ml,
whereas there was a tendency towards lower Cmax for the evening dosing having a mean of 24 pg/
ml. The maximum difference from placebo was observed 1 to 3 hours post-dose with a 40 to 50%
suppression consequent to morning dose, and about 75% suppression after pre-dinner and evening
dose, due to the increase bone resorption as a result of circadian variation.
Conclusion: The study suggests that orally administered 0.8 mg of salmon calcitonin was effective
in suppression of serum CTX irrespective of time of dosing. The pre-dinner dosing resulted in
optimum efficacy response corresponding to an overall suppression of bone resorption by 25%.
Trial registration: NCT00411125
Background
Calcitonin (CT) is a 32 amino-acid hormone produced by
parafollicular cells (C-cells) in the thyroid gland [1],
secreted in response to excess calcium in the serum [2].
Binding of calcitonin to the calcitonin receptor on osteo-
clasts results in a reduction in a raid bone resorption [3-
5]. Salmon calcitonin is among to most potent calciton-
ins, and belongs to the teleost/avian family[1]. Salmon
calcitonin (sCT) is approved for the treatment of oste-
oporosis and other diseases involving accelerated bone
turnover [6,7]. Preliminary evidence suggests that calci-
tonin may be a potential treatment for osteoarthritis that
also entails increased osteoclast function [8-10].
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Calcitonin treatment has until now been limited to either
subcutaneous or intranasal calcitonin administration [6].
An increasing amount of studies have focused on provid-
ing an oral formulation, which includes but not are lim-
ited to these novel oral delivery methods [11-22]. 5-
CNAC is the carrier responsible for absorption from the
intestinal lumen into the bloodstream of calcitonin
[6,8,9]. 5-CNAC is part of the Eligen technology, that
employs low molecular weight compounds that interact
weakly and non-covalently with proteins increasing its
lipophilicity and thereby its ability to cross the gastroin-
testinal epithelium [23]. The carrier, 5-CNAC, enable sys-
temic absorption of the drug via transcellular absorption
[24-26]. This oral formulation in combination with sCT,
has been demonstrated to be safe and efficaciously in a 3
month Phase II study in postmenopausal women [6].
Oral drug delivery of small peptides is hampered by an
array of obstacles [12], including but not limited to degra-
dation by proteolytic enzymes in the digestive tract and
secondary intestinal uptake [12,13]. These difficulties are
best illustrated by the complete lack of peptides in oral
formulations approved by the FDA and EMEA. In addi-
tion to innovative strategies for improved uptake, [13]
considering drug delivery based on knowledge of physio-
logical bone turnover may further improve efficacy
parameters. Diurnal variation is a well-established and
important parameter of bone turnover, in which post-
prandial decreases in bone resorption result in an approx-
imately 50% decrease in bone resorption compared to
that of fasting individuals, and an equally large increase in
bone resorption during the night [27,27-29]. This might
attenuate the potential efficacy on bone resorption if co-
administrated with food intake in the morning after the
fasting period, in face of that of administration at a more
optimal time of the day, i.e. in prior to bedtime or later in
the evening where resorption peaks during the diurnal
resorption period [27,27,28]. As bone resorption is
decreased more than 50% after meal intake, additional
benefits of anti-resorptives drugs may be limited, unless
they provide sustained suppression in contrast to the
completely reversible effect observed with calcitonin.
Bone resorption can be assessed by measurement of colla-
gen type I degradation products. 90% of the protein of
bone is collagen type I, that during bone resorption by
osteoclasts is degraded by the cysteinse protease cathespin
K[5]. This results in generation of CTX-I (C-terminal telo-
peptide of collagen type I), that is a specific fragment of
collagen type I exclusively generated by cathepisn K
[30,31]. CTX-I fragments have been used as a surrogate
measure of bone resorption for in vitro, preclinical and
clinical studies [30,32].
The aim of the current study was to investigate the diurnal
variation in bone resorption and to investigate the effect
of oral calcitonin given as a morning dose, a pre-dinner
dose, and an evening dose in healthy postmenopausal
women. The absorption of calcitonin was assessed by
measurement of plasma sCT concentrations, and bone
resorption by the biochemical marker serum CTX-I
(serum C-terminal telo-peptide of collagen type I). In




SMC021 A/C is an oral formulation of salmon calcitonin.
The investigational drug consisted of 0.8 mg of recom-
binant sCT and 200 mg of 5-CNAC, {8-(N-2-hydroxy-5-
chloro-benzoyl)-amino-caprylic acid)} a unimolecular
enhancer of gastrointestinal peptide absorption devel-
oped by Emisphere Technology, Inc. and licensed to
Novartis.
Study design
The study was conducted in accordance with Helsinki
Declaration II, and approved by local Ethical Committees
(EudraCT number: 2006-002685-19), with the trial regis-
tration number NCT00411125. Written informed consent
was obtained for all participants. The study was approved
by the local Danish ethical committee, Copenhagen
County.
The study was a randomized, double-blind, double-
dummy, placebo-controlled study to assess the pharma-
cokinetic (PK) and pharmacodynamic (PD) profiles of
two different variants of 0.8 mg of oral sCT (SMC021) and
the effect of timing of drug intake in healthy postmeno-
pausal women. The two different variants consisted of two
production batches of the same product: Batch 002 was a
pilot scale equipment batch and batch 010 a full scale pro-
duction. The inclusion criteria requested that generally
healthy ambulatory female volunteers were aged between
40–70 years and having passed a natural or surgical men-
opause at least 5 years before entering the study and being
without diseases or medications known to affect bone
metabolism.
The study was divided into 3 separate parts with timing of
dosing and intake of meal at pre-defined time-points as
outlined in Table 1. After consenting the women were
allocated to participate in one of the parts.
Part 1 included a total of 42 subjects and was aimed at
investigation of PK and PD of two variants of 0.8 mg of
sCT and placebo given in the morning at 8:00. At the start
of the study, subjects were randomized to receive active
treatment (the two production variants) and placebo in a
specific order. Part 1 had 3 treatment periods of 3 days,
with study drug intake in the morning of each day. The
wash-out period was at least 3 days between treatmentBMC Clinical Pharmacology 2008, 8:12 http://www.biomedcentral.com/1472-6904/8/12
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periods. After an overnight fast, subjects received the dose
of drug with 200 ml of water and was sampled immedi-
ately before drug intake, and at 5, 10, 15, 30, 45 minutes,
1, 1 1/2, 2, 2 1/2, 3 hours, and every hour until the second
dosing 24 hours after first dose. Meals were served at
scheduled time points as outlined in Table 1. No other
food consumption at any other time point was allowed,
but intake of water was allowed from 1 hour after dosing.
Part 2 included a total of 20 subjects and was aimed at
investigation of PK and PD of an oral dose of 0.8 mg of
sCT (batch 010) and placebo given pre-dinner at 17:00. At
the start of the study, subjects were randomized to receive
active treatment and placebo in a specific order. The study
included 2 treatment periods with a single dosing each
and with a wash-out period of at least 3 days between
treatment periods. On the first day of treatment, the sub-
jects arrived at the clinic during the morning, had a meal
at 13:00 and received the first dose at 17:00. Additional
meals were served at the scheduled time points, and the
24-hour blood sampling schedule was similar to that
described in Part 1.
Part 3 included a total of 19 subjects and was aimed at
investigation of PK and PD of an oral dose of 0.8 mg of
sCT (batch 010) and placebo given in the evening at
22:00. The randomization, treatment periods, and wash-
out period were similar to Part 2. On the first day of treat-
ment, the subjects arrived at the clinic at dinner time, had
a meal at 18:00 and received the first dose at 22:00. Addi-
tional meals were served at the scheduled time points, and
the 24-hour blood sampling schedule was similar to that
described in Part 1.
The plasma and serum samples were stored at -20°C until
analysis. For PK assessment, plasma sCT was measured in
the blood samples collected in the period of 0–4 hours
after drug intake.
The concentration of plasma sCT was measured by a
chemiluminescence-based immunoassay as previously
described [6]. Values measured below the lower limit of
quantification of 2.5 pg/ml was assigned the value of 2.5
pg/ml. The assay was a two-site immunometric type
employing two antibodies, one biotinylated and the other
acridium labeled. Specificity has been tested against syn-
thetic fragments of sCT and against human as well as eel
calcitonin and negligible interaction has been found over
the range of standard curve. The lower limit of quantifica-
tion (LLOQ) was 2.5 pg/ml. The quality control samples,
ranging from 2.5 pg/ml to 700 pg/ml, were prepared daily
and measured in 3 to 5 replicates. The overall accuracy
and precision (CV) of the control samples measured on
11 different days was 101.3% and 10.1% for 2.5 pg/ml
concentration and 94.3% and 6.0% for 700 pg/ml con-
centration, respectively.
The Serum CTX-I test is a sandwich enzyme enzyme-
linked immunosorbent assay (ELISA) employing two
monoclonal antibodies both recognizing the C-telopep-
tide of the α1-chain in type I collagen [33]. The mono-
clonal antibodies, i.e. MAb F1103 and MAb F12,
recognize the eight amino acid sequence EKAHD-β-GGR,
where D- β -G denotes an isomerised bond between aspar-
tate and glycine, and both antibodies require the presence
of a free C-terminal arginine for binding. Cathepsin K,
secreted by the osteoclast, is responsible for the proteo-
lytic cleavage exposing the free C-terminal arginine [30].
The sandwich construction assures that only cross-linked
di-peptides, i.e. EKAHD-β-GGR × EKAHD-β-GGR, are
measured by the Serum CTX-I ELISA. The measuring range
is 0.020–3.380 ng/ml, and in this range the intra- and
interassay coefficient of variation is < 3.0 and < 10.9%,
respectively, and the dilution recovery 103%. The refer-
ence range (mean (95% confidence interval) for postmen-
opausal and premenopausal women as well as men is
0.439 ng/ml (0.142 – 1.351 ng/ml), 0.287 ng/ml (0.112
– 0.738 ng/ml), and 0.294 ng/ml (0.115 – 0.748 ng/ml),
respectively, according to the manufacturer (Immunodi-
agnostic Systems Nordic, Herlev, Denmark)[33].
Statistical analysis
The sample size was calculated separately for the three
parts of the study. With the primary objective of investi-
Table 1: described the study design in the 3 parts with the time of meal and dosing of oral calcitonin.
Study Design: Timing of Dosing and Meal Intake
08:00 09:00 13:00 17:00 18:00 22:00 08:00 09:00 13:00 17:00 18:00 22:00
P a r t  1  M o r n i n g  D o s i n g D o s e M e a l M e a l - M e a l - E n d xxxxx
Part 2 Pre-dinner Dosing x x Meal Dose Meal - - Meal Meal End x x
P a r t  3  E v e n i n g  D o s i n g xxxx M e a l D o s e - M e a l M e a l - M e a l E n d
(-) Denotes study period with no action. (X) Denotes not part of study period.BMC Clinical Pharmacology 2008, 8:12 http://www.biomedcentral.com/1472-6904/8/12
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gating the PK profiles of the two variants of sCT in Part 1,
a sample size of 42 subjects was necessary to have at least
85% power to reject the null hypothesis that the absolute
difference in the loge-transformed Cmax of the two variants
was above 0.693 using a one-sided t-tests at the 5% signif-
icance level, based on a two-arm cross-over design. Trans-
formed back to the original scale, the null hypothesis
corresponds to ratio less than 0.5 or greater than 2.0. The
alternative hypothesis was that the difference in mean
loge-transformed Cmax between the two variants was 0.05
(that is, the Cmax of the batch 010 variant was 95% of the
batch 002 variant and that the between-subjects standard
deviation on the loge scale was 1.0. Similar sample size
calculations applied for AUC0–4 hrs.
For Parts 2 and 3, a sample size of 20 subjects was neces-
sary to have at least 90% power to reject the null hypoth-
esis that the difference in the serum CTX AUC0–24 hrs
between sCT and placebo was less than 0.150 using a one-
sided t-test at the 5% significance level using a two-arm
cross-over design. The between-subjects common stand-
ard deviation was assumed to be 0.11.
No randomization of subjects was performed to Parts 1, 2
or 3 of the study, therefore comparisons between the three
parts should be made with care as they may be affected by
bias.
The trapezoidal method was applied for the calculation of
AUC0–4 hrs of plasma sCT and relative change in serum
CTX after dosing. The relative value of serum CTX was cal-
culated as percentage of the individual pre-dose value
within each treatment period. As a post-hoc unplanned
analysis, the relative change of serum CTX was deter-
mined as 100% minus the relative value of serum CTX.
The AUC of plasma sCT, and the time course data of
plasma sCT, serum CTX, and relative value of serum CTX
were logarithmically transformed to obtain normality and
symmetry of variances.
Comparison of the two variants of sCT on the pharmacok-
inetic parameters of sCT Cmax and sCT AUC0–4 hrs investi-
gated in part 1 was performed in a linear mixed effect
model with parameter as response variable and variant
(var002, var010) and treatment sequence (1,2,3) as fixed
effects and subject as random effect. In each dose time
group the treatment response on sCTX AUC0–24 hrs was
assessed in a linear effect model with treatment group
(var002, var010, placebo) and treatment sequence (1,2,3)
as fixed effects and subject as random effect. Comparison
of the parameters of sCT Cmax and sCT AUC0–4 hrs in the
active treatment groups among the dose time groups was
performed in a linear effect model with parameter as
response variable and dosing time (part 1,2,3) and
sequence (1,2,3) as fixed effects. In the comparison of the
active treatment response of var010 on sCTX AUC0–24 hrs
among the dose time groups, first the placebo-corrected
values were calculated by subtracting the placebo AUC
from the treatment AUC for each individual subject. The
placebo-corrected AUC was then compared among the
dose time groups in a linear effect model having dosing
time (part 1,2,3) as fixed effect. The significance levels
were Tukey-Kramer adjusted in the multiple comparisons.
A difference was considered significant if p-value was less
than 5%. All statistical calculations were performed using
the SAS software package (release 9.1, SAS Institute Inc.,
Cary, NC, USA).
Results
The age characteristics of the study participants are given
in Table 2. The subjects were aged between 57 and 71
years, and comparable between the three parts of the
study.
The effect of time of dosing on the absorption of SMC021
is shown in Figure 1. The sCT appeared rapidly in plasma
with a median time to reach maximum (Tmax) at about 30
minutes post-dose irrespective of dosing time (Table 3).
Following Tmax  the plasma concentration returned to
baseline approximately 2 hours after dosing. Morning and
pre-dinner dosing gave a maximum geometric mean Cmax
of 45 pg/ml, whereas there was a tendency towards a
lower Cmax of 24 pg/ml for the evening dosing although
this was statistically non-significant (ANOVA p = 0.14;
morning versus evening dosing p = 0.05). The total expo-
sure, AUC0–4 hrs of plasma sCT in the period between dos-
ing and 4 hours post-dose was in the range of 28 to 36
(pg/ml × hrs) and was not influenced by time of dosing
(Figure 2, Table 3) (p = 0.61). The two variants were found
to be similar in terms of the pharmacokinetic parameters
of AUC0–4 hrs and Cmax based on the pre-specified require-
ments in the protocol: the 95% confidence interval for the
ratio in log-transformed AUC0–4 hrs and Cmax between the
two variants was 82% to 125%, and 69% to 120%, respec-
tively, both within the 50% to 200% defined in the proto-
col. There was no statistically significant effect of
treatment sequence and also the pharmacodynamic effect
of sCTX AUC0–24 hrs was comparable between the 2 vari-
ants (p = 1.00). The efficacy of the administered SMC021
was assessed by the pharmacodynamic profile of bone










Age (years) 65.5 (3.8) 64.6 (4.2) 64.4 (2.9)
Values are mean (SD)BMC Clinical Pharmacology 2008, 8:12 http://www.biomedcentral.com/1472-6904/8/12
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resorption measured by the biochemical marker of CTX in
serum samples obtained until 24 hours after dosing.
Overall, dosing with SMC021 resulted in a significant sup-
pression of serum CTX over placebo irrespective of dosing
time (Figure 3). Following the morning dose of SMC021,
serum CTX decreased to a nadir 3 to 4 hours post-dose
(Figure 3). At the time of maximum suppression, the level
of serum CTX was decreased to 22% relative to the pre-
dose value. The maximum difference of 40 to 50% from
placebo was found 1 to 2 hours after dosing. A return to
the placebo level was seen 12 hours post-dose following
morning dosing. A higher suppression of serum CTX was
found for pre-dinner and evening dosing with a maxi-
mum difference of about 75% from placebo at 1 to 3
hours after dosing due to the circadian variation in serum
CTX observed in the placebo group. In addition the pre-
dinner dose tended to have a prolonged period of action
with a remission to the placebo level seen 16 hours post-
dose. There were no statistical differences between the two
variants on pharmacodynamic parameters.
The total response of dosing with SMC021 was assessed as
AUC of change from the baseline levels during the 24-
hour follow-up period. The placebo-corrected AUC0–24
hrs related to the morning dose of SMC021 was statisti-
cally highly significant (p < 0.001) with a mean value of -
232 (% × hrs) (Figure 4). This decrease would correspond
to a permanent overall suppression of bone resorption by
10%. The pre-dinner dose was twice as effective in sup-
pression of serum CTX giving a mean AUC0–24 hrs of -
603 (% × hours) (p < 0.001) corresponding to an overall
suppression of 25%. The AUC0–24 hrs of the evening
dose was at the same level of magnitude at -538 (% × hrs)
(p = 0.06) although there seemed to be a higher inter-indi-
vidual variation in the response.
Discussion and conclusion
We have investigated the effect of drug timing on the bio-
availability and pharmacokinetic profile of a single dose
of 0.8 mg of salmon calcitonin given orally with the aim
to determine the best timing of dose for optimal bone
marker efficacy. We asked the question if dosing in a not
fully fasting state, i.e. pre-dinner, or before bedtime as
compared to an overnight fasting state before breakfast,
would result in clinical efficacy.
In this closely monitored study, the results of the placebo
groups clearly show the intrinsic diurnal variation in bone
resorption with suppression consequent to meal intake. A
decrease in bone resorption could be observed 1 hour
postprandial both after the breakfast meal at 09:00, lunch
at 13:00, and dinner at 18:00. These observations are in
line with those previous observed post prandially
[27,28,34]. Importantly, the postprandial decrease in
bone resorption was largest in the morning, suggesting
that longer fasting periods are needed for obtaining the
full effect on bone resorption post prandially.
The absolute levels of bone resorption were different at
the different time of day, in accordance with the diurnal
variation [29]. Calcitonin Cmax or AUC0–4 hrs was similar
following dosing in the morning and evening, although
there was a tendency towards lower absorption in the
evening. This did however not reach statistical signifi-
cance, maybe in part due to the inter-individual variation.
In contrast, this resulted in higher decreases in bone
resorption taken when bone resorption was higher, i.e.
before dinner and during the night. This may partly be
due to lack of the postprandial decrease in bone resorp-
tion after the long fating period in the morning and partly
because of inhibition of bone resorption at higher levels,
i.e. at peak intensities during the night, compared to that
of the morning.
With respect to safety issues, this current oral formulation
of sCT have previously been evaluated [6] in a three
months safety and efficacy study. There were no safety
concerns with this oral formulation.
With respect to longer term efficacy, several parameters
need to be evaluated. Bone formation in healthy individ-
uals is tightly coupled to bone resorption, in which an
equal amount of bone formation is made in response to
that of bone resorption [35,36]. Normally, a secondary
decrease in bone resorption is seen with anti-resorptive
drugs secondary to that in bone resorption [30,37]. Inter-










Cmax (pg/ml) 45.1 (39.1–52.0) 44.7 (31.8–62.9) 23.8 (16.9–33.5)
Tmax (minutes) 30 (15–30) 30 (15–30) 30 (30–33.8)
AUC0–4 hrs 30.6 (27.2–34.4) 36.3 (28.6–46.1) 28.1 (21.6–36.6)
AUC0–4 hrs and Cmax is given as geometric mean (mean ± 1SEM range) and Tmax as median (25–75 percentile)BMC Clinical Pharmacology 2008, 8:12 http://www.biomedcentral.com/1472-6904/8/12
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estingly, with this present oral formulation an inhibition
in bone resorption without the secondary effect on bone
formation was observed, in the 3 months efficacy study
[6]. This might be as a consequence to the transient inhi-
bition of bone resorption in contrast to other treatments
with sustained inhibition [36], although this remains
speculative. Thereby, addition dosing may not result in
the theoretical additive effect, as a consequence to a sec-
ondary inhibition of bone formation.
Time course of plasma sCT in each time dose group Figure 1
Time course of plasma sCT in each time dose group. 
Full line shows the results of 0.8 mg of oral sCT and the dot-
ted line that of placebo. Morning dose (n = 42); pre-dinner 
dose (n = 20); and evening dose (n = 19). Values given are 
geometric mean ± 1 SEM.
Cmax and AUC0–4 hrs of plasma sCT in the 4 hours following  one single dose of 0.8 mg of oral sCT in each time dose  group corrected for AUC of the placebo groups Figure 2
Cmax and AUC0–4 hrs of plasma sCT in the 4 hours fol-
lowing one single dose of 0.8 mg of oral sCT in each 
time dose group corrected for AUC of the placebo 
groups. Morning dose (n = 42); pre-dinner dose (n = 20); 
and evening dose (n = 19). Values given are geometric mean 
± 1 SEM.BMC Clinical Pharmacology 2008, 8:12 http://www.biomedcentral.com/1472-6904/8/12
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In the current study, bone resorption was evaluated by
CTX-I, a marker of bone resorption [38]. An extensive
amount of research have been conducted with CTX-I, in
which effects on food intake and circadian variation are
well established parameters [27,29,34,39], and changes in
CTX-I accurately reflects changes in bone resorption both
in vitro and in vivo [35,40]. Changes in bone resorption
markers, in response to food intake have been reported
Time course of absolute levels of serum CTX in each time  dose group Figure 3
Time course of absolute levels of serum CTX in each 
time dose group. Closed circles show the results of 0.8 mg 
of oral sCT and the open circles that of placebo. The figures 
show results of the full follow-up period of 24 hours. Morn-
ing dose (n = 42); pre-dinner dose (n = 20); and evening dose 
(n = 19). Values given are geometric mean ± 1 SEM.
AUC of absolute (A) and relative (B) change in serum CTX in  the 24 hours following one single dose of 0.8 mg of oral sCT  in each time dose group corrected for placebo AUC of the  individual subject Figure 4
AUC of absolute (A) and relative (B) change in 
serum CTX in the 24 hours following one single dose 
of 0.8 mg of oral sCT in each time dose group cor-
rected for placebo AUC of the individual subject. 
Morning dose (n = 42); pre-dinner dose (n = 20); and evening 
dose (n = 19). Values given are geometric mean ± 1 SEM. The 
level of significance denotes difference from placebo: **p < 
0.01; *** p < 0.001.BMC Clinical Pharmacology 2008, 8:12 http://www.biomedcentral.com/1472-6904/8/12
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for other markers of bone resorption, whereas markers of
osteoclast number such as TRAP does not change [41].
Taken together, even though that we in the present study
have used the most well-established bone resorption
markers, other markers of osteoclast number and function
such as TRAP, NTX and cathepsin K [30] may in addition
shed addition light into the mode of action of sCT on
bone resorption.
For optimization of the efficacy of anti-resorptive drugs,
with special emphasis on completely reversible interven-
tions such as calcitonin, the timing of drug dosage is
important. The diurnal variation in bone resorption,
which is tightly associated with meal intake, is principal in
bone biology, and allows for timing of dosage at peak
bone resorption periods. Our data suggest that pre-dinner
dosing was more effective in achieving absorption (in fast-
ing conditions) and in the suppression of serum CTX in
comparison with morning or bed-time dosing. These
investigations and data are instrumental in understanding
and utilizing natural circadian rhythms for optimising
drug efficacy.
In addition to the primary objectives we investigated the
comparability of two production batches of oral calci-
tonin in terms of absorption and surrogate efficacy mark-
ers. The two variants investigated were shown to be
comparable in terms of absorption and of effect on bone
resorption, serum CTX.
In conclusion, our data suggest that sCT given pre-dinner
results in improved absorption and changes in serum CTX
compared to that of dosing in the morning or at bed-time.
Further clinical studies are needed to investigate these
promising data for the treatment of osteoporosis.
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